2019 American Association for Cancer Research (AACR) Annual Meeting

Schedule of DCTD Presentations

Several members of DCTD’s staff will present information at the AACR Annual Meeting in Atlanta, GA, March 29 – April 3, 2019.

• Oral Presentations
• Poster Presentations
• Meet-the-Expert Presentations
• DCTD Staff Kiosk Schedule

Oral Presentations

Time	Title	Presenter/Staff Authors	Location
Saturday, March 30
5:30PM – 7:30 PM	Careers in clinical and translational cancer research roundtable	James Doroshow, MD Office of the Director Percy Ivy, MD Jeffrey Moscow, MD Malcolm Smith, MD, PhD Cancer Therapy Evaluation Program	Atrium Ballroom A Marriott
Sunday, March 31
12:15PM – 1:45 PM	The Cancer Moonshot: Rapid Launching of New Research Programs	Nita Seibel, MD Malcolm Smith, MD, PhD Percy Ivy, MD Cancer Therapy Evaluation Program Irina Lubensky, MD Cancer Diagnosis Program	Room A406
1:00 PM – 2:45 PM	Hyper-progression and immuno-oncology: Scientific, clinical, and regulatory challenges	Elad Sharon, MD, MPH Cancer Therapy Evaluation Program	Room A402
4:05 PM – 4:20 PM	A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) S1609: The neuroendocrine cohort	Helen Chen, MD Elad Sharon, MD, MPH Cancer Therapy Evaluation Program	Room A411
Tuesday, April 2
10:30 AM – 12:15 PM	Funding Opportunities for Cancer Research at Multiple NIH Institutes and Centers	Julia Arnold, PhD Translational Research Program Sundar Venkatachalam, PhD Developmental Therapeutics Program	Room A406
12:30 PM – 2:15 PM	Technology Transfer and Intellectual Property: Financial and Career Opportunities for Research Scientists	Jason Cristofaro, PhD, JD	Room A406
3:00 PM – 5:00 PM	Comparison of PDX, PDC, and PDOrg models from the National Cancer Institute’s Patient-Derived Models Repository (PDMR)	Yvonne Evrard, PhD Developmental Therapeutics Program	Room A311
Wednesday, April 3
10:15 AM – 11:15 AM	NCI-Supported Biospecimen Resources Available to the Cancer Research Community	Irina Lubensky, MD Joanne Demchok, MS Cancer Diagnosis Program	Room A406

Poster Presentations

Time	Title	Location
Sunday, March 31
1:00 PM – 5:00 PM	Molecular analysis for therapy choice (NCI-MATCH, EAY131) arm Z1B: Phase II trial of palbociclib for CCND1, 2 or 3 amplified tumors	Section 41; Abstract LB-010/2
1:00 PM – 5:00 PM	Phase I trial of recombinant human interleukin 15 (rhIL-15) in combination with nivolumab and ipilimumab in refractory cancers	Section 41; Abstract LB-015/7
1:00 PM – 5:00 PM	Temozolomide resistant MGMT negative/MMR proficient cancer cells rely on ATR signaling and homologous recombination for DNA repair and survival	Section 11; Abstract 270/14
Monday, April 1
8:00 AM – 12:00 PM	Systemic establishment of robustness and standards in xenograft experiments and analysis	Section 4; Abstract 1054/5
8:00 AM – 12:00 PM	Xenograft-associated B cell lymphoproliferative disease (XABLD) as a surrogate model to study Epstein-Barr virus (EBV) driven B cell diseases	Section 4; Abstract 1056/7
8:00 AM – 12:00 PM	The PDX Data Commons and Coordinating Center (PDCCC) for PDXNet in support of preclinical research	Section 4; Abstract 1074/25
1:00 PM – 5:00 PM	DNA damage response and therapeutic activity following once-daily administration of the Wee 1 inhibitor AZD1775 (adavosertib)	Section 16; Abstract CT099/23
1:00 PM – 5:00 PM	Effect of 2D vs. 3D, exposure time, media and additives on growth and EGFR inhibitor response in patient-derived NSCLC lines	Section 13; Abstract 2170/21
1:00 PM – 5:00 PM	A survey of molecular factors of DNA methylation and demthylation in a broad range of cancer cell lines	Section 31; Abstract 2479/19
1:00 PM – 5:00 PM	MutSpliceDB: A database of splice sites mutations effects	Section 31; Abstract 2480/20
Tuesday, April 2
8:00 AM – 12:00 PM	NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing BRCA1 and BRCA2 mutations	Section 16; Abstract CT138/4
8:00 AM – 12:00 PM	NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activation mutations	Section 16; Abstract CT139/5
8:00 AM – 12:00 PM	Lymphoblast cells secrete putative protein factors in response to high-dose radiation causing anti-tumor effect in lung cancer cells	Section 8; Abstract 2920/8
8:00 AM – 12:00 PM	Comparison of genomic biomarkers identified by the whole exome, RNASeq and whole genome sequencing pipelines developed for the PDMR	Section 31; Abstract 3385/16
1:00 PM – 5:00 PM	In vivo evaluation of the Menin inhibitor VTP-50469 against Ewing sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC)	Section 11; Abstract 3835/10
1:00 PM – 5:00 PM	Comparison of thio-deoxy-cytidine (TdCyd) and aza-thio-deoxy-cytidine (Aza-TdCyd) in solid and liquid tumor cell lines and PPTC pediatric xenografts	Section 11; Abstract 3839/14
1:00 PM – 5:00 PM	Knockout of DNMT1 using CRISPR gene-editing technology confers resistance to DNMT inhibitors in human breast cancer cells	Section 11; Abstract 3847/22
1:00 PM – 5:00 PM	In vivo evaluation of the LSD1 inhibitor SP-2577 against Ewing sarcoma and rhabdomyosarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC)	Section 11; Abstract 3848/23
1:00 PM – 5:00 PM	Association of transcriptional levels of folate-mediated one-carbon metabolism related genes in cancer cell lines with drug treatment response	Section 29; Abstract 4246/15
Wednesday, April 3
8:00 AM – 12:00 PM	A phase II trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed metastatic colorectal carcinoma	Section 41; Abstract LB-293/10

Meet-the-Expert Presentations — NCI Exhibit Booth #2111

Time	Topic	Presenter
Sunday, March 31
3:00 – 3:30 PM	NCI’s Cancer Complementary and Alternative Medicine Programs	Libin Jia, MD Office of Cancer Complementary and Alternative Medicine
3:30 – 4:00 PM	SPOREs: 25 Years of Translational Team Research at the NCI	Julia Arnold, PhD Translational Research Program
Monday, April 1
11:30 AM – 12:00 PM	In Vitro and In Vivo Models from the NCI Patient-Derived Models Repository	Yvonne Evrard, PhD Developmental Therapeutics Program
2:00 – 2:30 PM	Funding Opportunity for Advancing Cancer Immunotherapy by Mitigating Immune-related Adverse Events (irAE)	Elad Sharon, MD, MPH Cancer Therapy Evaluation Program
3:00 – 3:30 PM	Future of NCI-MATCH Trial	Lyndsay Harris, MD Cancer Diagnosis Program
3:30 – 4:00 PM	The NCI Formulary: A Cancer Moonshot Initiative	Jason Cristofaro, PhD, JD Office of the Director
Tuesday, April 2
11:30 AM – 12:00 PM	New NCI Resources for Development of Immunotherapy Products	Connie Sommers, PhD Developmental Therapeutics Program
2:00 – 2:30 PM	The NCI Molecular Characterization Laboratory: Activities and Resources Available	Chris Karlovich, PhD Developmental Therapeutics Program
2:30 – 3:00 PM	Cancer Diagnosis Programs and Funding Opportunities	Aniruddha Ganguly, PhD Cancer Diagnosis Program
3:30 – 4:00 PM	Radiation Research Program	Pat G. Prasanna, PhD Mansoor M. Ahmed, PhD Radiation Research Program

DCTD Staff Kiosk Schedule — Cancer Treatment and Diagnosis — NCI Exhibit Booth #2111

Time	DCTD Staff
Sunday, March 31
1:00 – 3:00 PM	Aniruddha Ganguly, PhD Cancer Diagnosis Program Timothy Hefferon, PhD NLM/National Center for Biotechnology Information
3:00 – 5:00 PM	Leah Hubbard, PhD Translational Research Program
Monday, April 1
9:00 – 11:00 AM	Sudhir Kondapaka, PhD Developmental Therapeutics Program
11:00 AM – 1:00 PM	Yali Fu, PhD Developmental Therapeutics Program
1:00 – 3:00 PM	Beverly Teicher, PhD Developmental Therapeutics Program Timothy Hefferon, PhD NLM/National Center for Biotechnology Information
3:00 – 5:00 PM	Steve Nothwehr, PhD Translational Research Program
Tuesday, April 2
9:00 – 11:00 AM	Weiwei Chen, PhD Developmental Therapeutics Program
11:00 AM – 1:00 PM	Nina Lukinova, PhD Cancer Diagnosis Program
1:00 – 3:00 PM	Rose Aurigemma, PhD Developmental Therapeutics Program
3:00 – 5:00 PM	Joanne Demchok, MS Cancer Diagnosis Program
Wednesday, April 3
9:00 AM – 12:00 PM	Aniruddha Ganguly, PhD Cancer Diagnosis Program